作者: 斗爭(zhēng) 時(shí)間: 2025-3-21 20:58
Springer Series in Optical Sciencesariates, and maximizing treatment benefit. In the latter case, adaptive allocation strategies aim to treat patients as ethically as possible, often by minimizing the expected number of treatment failures. These “optimal designs” achieve this minimization through algorithms and functions of success probabilities in each group of subjects.作者: 艦旗 時(shí)間: 2025-3-22 00:42
New Measurements with Optical Molassesand obtain faster approval of the drug globally. At the same time, the MRCT strategy is expected to maintain the sample size at the similar level, i.e., without significantly driving up the cost and slowing down the speed of the development.作者: 能得到 時(shí)間: 2025-3-22 05:51 作者: myopia 時(shí)間: 2025-3-22 11:02
,Design and Data Analysis of Multiregional Clinical Trials (MRCTs)—Theory and Practice,and obtain faster approval of the drug globally. At the same time, the MRCT strategy is expected to maintain the sample size at the similar level, i.e., without significantly driving up the cost and slowing down the speed of the development.作者: Gene408 時(shí)間: 2025-3-22 13:01 作者: 沒(méi)花的是打擾 時(shí)間: 2025-3-22 20:23
Laser Raman spectroscopy of gases,untry and in other types of patient-based research (such as observational studies), this chapter will primarily focus on assembling and documenting the types of evidence needed to facilitate reviews of key study endpoints by the United States (US) Food and Drug Administration (FDA).作者: 易達(dá)到 時(shí)間: 2025-3-22 23:07 作者: 斜坡 時(shí)間: 2025-3-23 05:24
Springer Series in Optical Sciencesthe concept of clinical trial simulation is introduced, as well as the key components of the simulation process with a few examples of how scenario planning can be done to address specific concerns that are typically raised in drug development.作者: HACK 時(shí)間: 2025-3-23 06:16 作者: infantile 時(shí)間: 2025-3-23 09:49
Patient-Reported Outcome Measures: Development and Psychometric Evaluation,untry and in other types of patient-based research (such as observational studies), this chapter will primarily focus on assembling and documenting the types of evidence needed to facilitate reviews of key study endpoints by the United States (US) Food and Drug Administration (FDA).作者: grenade 時(shí)間: 2025-3-23 16:40
Interim Analyses: Design and Analysis Considerations for Survival Trials When Hazards May Be Nonpro), Gould (.) and Shih (.) ushered in the era of adaptive designs—statistical research in this area flourished for the next two decades. Group-sequential methods became viewed as part of the broader category of adaptive methods.作者: Melanocytes 時(shí)間: 2025-3-23 19:19 作者: 詢問(wèn) 時(shí)間: 2025-3-24 02:03
Phase I Cancer Clinical Trial Design: Single and Combination Agents,esigns are more likely to correctly select the MTD and less likely to overdose a large percentage of patients. The extensions of the BOIN design to drug combination trials are briefly discussed. The software to implement these innovative designs is described and provided.作者: prostatitis 時(shí)間: 2025-3-24 03:20
https://doi.org/10.1007/978-981-10-7829-3Clinical Trial Simulations; Optimal Protocol Design; Statistical Analysis; Recurrent Event Data Trials; 作者: AGOG 時(shí)間: 2025-3-24 09:38 作者: 實(shí)現(xiàn) 時(shí)間: 2025-3-24 14:19 作者: 不幸的人 時(shí)間: 2025-3-24 14:59
Springer Series in Optical Sciencesibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent, and retrospective adaptive designs. An adaptive design is flexible in modifying trial and/or statistical procedures of on-going clinical trials. However, it is a c作者: 解脫 時(shí)間: 2025-3-24 22:21 作者: 紅潤(rùn) 時(shí)間: 2025-3-24 23:33 作者: languid 時(shí)間: 2025-3-25 06:03 作者: flutter 時(shí)間: 2025-3-25 08:25
Springer Series in Optical Sciences novel designs, including the continual reassessment method (CRM), the Bayesian model averaging CRM (BMA-CRM), the modified toxicity probability interval (mTPI) design, the Bayesian optimal interval (BOIN) design, and the Keyboard design. We discuss the pros and cons of these designs. Numerical stud作者: GIDDY 時(shí)間: 2025-3-25 12:31
Laser Cooling and Trapping of Atomsience with the conduct of other types of studies on human populations. Interim data monitoring, however, is often unfamiliar territory even to investigators who have been involved with other aspects of clinical trials. Yet there is some general agreement based on long experience, and some published 作者: 磨碎 時(shí)間: 2025-3-25 17:39 作者: 取消 時(shí)間: 2025-3-25 22:02 作者: 極小 時(shí)間: 2025-3-26 02:52
Laser Raman spectroscopy of gases,easures specifically designed to assess key endpoints in clinical trials, with the ultimate goal of supporting approval and/or labeling claims for pharmaceutical products. While many of our recommendations are broadly applicable to the development of PRO measures for use in clinical trials in any co作者: 知識(shí)分子 時(shí)間: 2025-3-26 06:12 作者: 印第安人 時(shí)間: 2025-3-26 10:52 作者: 內(nèi)向者 時(shí)間: 2025-3-26 14:17
Multi-Regional Clinical Trials, ICH-E17, and Subpopulations,ng in multiple regions using the same trial data in inside and outside of ICH (international council of harmonization) regions (Regions considered as ICH are European Union, US, Japan, Canada, and Switzerland).作者: 澄清 時(shí)間: 2025-3-26 19:37 作者: Monolithic 時(shí)間: 2025-3-26 21:08
M. Kaivola,S. A. Lee,O. Poulsen,E. RiisRecurrent event data analysis is common in clinical trials. Literature reviews indicate that most statistical models used for such data are often based on time to the first event or that events within a subject are considered to be independent.作者: 虛構(gòu)的東西 時(shí)間: 2025-3-27 02:34 作者: CRUE 時(shí)間: 2025-3-27 06:40
A Statistical Approach to Clinical Trial Simulations,Drug development is not for the fainthearted. We have heard repeatedly over the years regarding the process of bringing a new compound to the market, that every delay will add millions of dollars in added expenses and lost revenues.作者: Parabola 時(shí)間: 2025-3-27 13:13 作者: Intentional 時(shí)間: 2025-3-27 16:55 作者: REIGN 時(shí)間: 2025-3-27 20:25 作者: 影響帶來(lái) 時(shí)間: 2025-3-28 01:50
ICSA Book Series in Statisticshttp://image.papertrans.cn/b/image/188312.jpg作者: 純樸 時(shí)間: 2025-3-28 02:25
Biopharmaceutical Applied Statistics Symposium978-981-10-7829-3Series ISSN 2199-0980 Series E-ISSN 2199-0999 作者: 確認(rèn) 時(shí)間: 2025-3-28 09:23 作者: Noisome 時(shí)間: 2025-3-28 14:25 作者: 費(fèi)解 時(shí)間: 2025-3-28 14:50
Adaptive Trial Design in Clinical Research,ibility and efficiency. Based on adaptations applied, adaptive designs can be classified into three categories: prospective, concurrent, and retrospective adaptive designs. An adaptive design is flexible in modifying trial and/or statistical procedures of on-going clinical trials. However, it is a c作者: coagulate 時(shí)間: 2025-3-28 20:44
Best Practices in Clinical Trial Simulations for Adaptive Study Designs,imulation has been used extensively in many areas such as aerospace engineering, weather prediction and automotive design. In recent years, simulation has become much more mainstream in clinical trial design. Simulated clinical trials are used to gain a much richer understanding of how a trial will 作者: panorama 時(shí)間: 2025-3-29 00:52 作者: 羊欄 時(shí)間: 2025-3-29 06:08 作者: airborne 時(shí)間: 2025-3-29 08:03
Phase I Cancer Clinical Trial Design: Single and Combination Agents, novel designs, including the continual reassessment method (CRM), the Bayesian model averaging CRM (BMA-CRM), the modified toxicity probability interval (mTPI) design, the Bayesian optimal interval (BOIN) design, and the Keyboard design. We discuss the pros and cons of these designs. Numerical stud作者: ABHOR 時(shí)間: 2025-3-29 12:29
Data Monitoring: Structure for Clinical Trials and Sequential Monitoring Procedures,ience with the conduct of other types of studies on human populations. Interim data monitoring, however, is often unfamiliar territory even to investigators who have been involved with other aspects of clinical trials. Yet there is some general agreement based on long experience, and some published 作者: 背帶 時(shí)間: 2025-3-29 16:16 作者: 嘲弄 時(shí)間: 2025-3-29 20:23
Multi-Regional Clinical Trials, ICH-E17, and Subpopulations,ng in multiple regions using the same trial data in inside and outside of ICH (international council of harmonization) regions (Regions considered as ICH are European Union, US, Japan, Canada, and Switzerland).作者: 委派 時(shí)間: 2025-3-30 00:51
Patient-Reported Outcome Measures: Development and Psychometric Evaluation,easures specifically designed to assess key endpoints in clinical trials, with the ultimate goal of supporting approval and/or labeling claims for pharmaceutical products. While many of our recommendations are broadly applicable to the development of PRO measures for use in clinical trials in any co作者: 送秋波 時(shí)間: 2025-3-30 06:29 作者: AGATE 時(shí)間: 2025-3-30 08:19
On Design and Analysis of Dose-Response Trials for Early Clinical Development,gmoidal . model). For the triple trends test, we also develop a procedure for calculating the sample size. The main goal of the research is to develop a likelihood inference on the effect of any given dose, which is not necessarily studied in the trial. In particular, we propose a likelihood test wi作者: insightful 時(shí)間: 2025-3-30 12:24 作者: 監(jiān)禁 時(shí)間: 2025-3-30 17:55
Choosing the Function of Baseline Run-in Data for Use as a Covariate in the Analysis of Treatment Dovariance structure specified as either AR (1) or compound symmetry (CS) with correlation coefficients of 0.1, 0.5 and 0.9. Our objective was to determine the best function of the baseline run-in data to use as a covariate in the comparative statistical analysis of the monthly treatment period data.
